Michael McClellan

618 citations
6 papers · 172 indexed · h-index 5
Topics
RNA modifications and cancer (2 papers)Cancer Genomics and Diagnostics (2 papers)Epigenetics and DNA Methylation (2 papers)

In The Last Decade

Michael McClellan

6 papers receiving 168 citations

Peers

Michael McClellan
Comparison fields: 5 of 41
  • Molecular Biology 138
  • Genetics 52
  • Cancer Research 35
  • Pediatrics, Perinatology and Child Health 18
  • Plant Science 16
Replace Nazmul Haque with:
Nazmul Haque United States
Michael Roßbach Singapore
Ian C. MacArthur United States
Luke Wojenski United States
Sandra Fert‐Ferrer France
Soichiro Kumamoto Japan
Ferdouse Begum United States
Zhilin Ning China
Aradhita Baral India
Shahrin Pereira United States
Michael McClellan relative to Nazmul Haque United States Nazmul Haque's profile →
Citations per field
00.5×2.6×
Nazmul Haque · 1×
Citations per year

Countries citing papers authored by Michael McClellan

Since Specialization
Citations

This map shows the geographic impact of Michael McClellan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael McClellan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael McClellan more than expected).

Fields of papers citing papers by Michael McClellan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael McClellan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael McClellan. The network helps show where Michael McClellan may publish in the future.

Co-authorship network of co-authors of Michael McClellan

This figure shows the co-authorship network connecting the top 25 collaborators of Michael McClellan. A scholar is included among the top collaborators of Michael McClellan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael McClellan. Michael McClellan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

6 of 6 papers shown
#WorkIndexed citations
1 80
2 9
3 32
4 34
5 15
6 2

About Michael McClellan

Michael McClellan is a scholar working on Cancer Research, Genetics and Molecular Biology, having authored 6 papers that have together received 172 indexed citations. Recurring topics across this work include RNA modifications and cancer (2 papers), Cancer Genomics and Diagnostics (2 papers) and Epigenetics and DNA Methylation (2 papers). The work is most often cited by research in Cancer Research (35 citations), Molecular Biology (138 citations) and Genetics (52 citations). Michael McClellan has collaborated with scholars based in United Kingdom, United States and France. Frequent co-authors include Skirmantas Kriaučionis, Markéta Tomková, Benjamin Schuster‐Böckler, Édith Heard, Felix Krueger, Wolf Reik, Jonathan Godwin, Job Dekker, Tatyana B. Nesterova and Michał R. Gdula. Their work appears in journals such as Nature Communications, British Journal of Cancer and eLife.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026